{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:53:32Z","timestamp":1789620812288,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.bbmt.2015.07.021","type":"journal-article","created":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T09:32:48Z","timestamp":1437903168000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-9623","authenticated-orcid":false,"given":"Attaphol","family":"Pawarode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Mineishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser A.","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung W.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Magenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Parkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Yanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Couriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.07.021_bib1","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bbmt.2015.07.021_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.07.021_bib3","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.07.021_bib4","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.07.021_bib5","unstructured":"National Comprehensive Cancer Network (NCCN) Multiple Myeloma Panel Members. NCCN Clinical Practice Guidelines in Oncology (NCCN\u00a0Guidelines), Multiple Myeloma, Version 4.2015. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#myeloma. 2015:Version 4.2015."},{"key":"10.1016\/j.bbmt.2015.07.021_bib6","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the ASBMT","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib7","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2005-05-1981","article-title":"Relationship of patient survival and chromosome anomalies detected in metaphase and\/or interphase cells at diagnosis of myeloma","volume":"106","author":"Dewald","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.021_bib8","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.021_bib9","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1200\/JCO.2005.17.129","article-title":"Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance","volume":"23","author":"Jaksic","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.021_bib10","first-page":"7","article-title":"Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy","volume":"16","author":"Tricot","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib11","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1200\/JCO.2005.05.023","article-title":"Prognostic and therapeutic significance of myeloma genetics and gene expression profiling","volume":"23","author":"Stewart","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.021_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation","volume":"325","author":"Gahrton","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.07.021_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbmt.2007.04.006","article-title":"Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma","volume":"13","author":"Kuruvilla","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.021_bib15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/bmt.2009.14","article-title":"Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect","volume":"44","author":"Khaled","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib16","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.021_bib17","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.bmt.1704670","article-title":"Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives","volume":"34","author":"Zeiser","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib18","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lokhorst","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.021_bib19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.bbmt.2015.02.012","article-title":"Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation","volume":"21","author":"Morris","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib20","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2014.04.027","article-title":"The Graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation","volume":"20","author":"Donato","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib21","first-page":"1","article-title":"Hematopoietic stem cell transplantation in multiple myeloma. A retrospective study of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","author":"Beaussant","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","article-title":"Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma","volume":"30","author":"Giralt","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib23","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1002\/cncr.25228","article-title":"Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up","volume":"116","author":"Shimoni","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2015.07.021_bib24","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.021_bib25","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.021_bib26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A\u00a0Comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.07.021_bib27","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.021_bib28","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A\u00a0prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.021_bib29","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/bmt.2012.173","article-title":"Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment","volume":"48","author":"Armeson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib30","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1182\/blood-2012-11-469452","article-title":"Autologous\/reduced-intensity\u00a0allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study","volume":"121","author":"Gahrton","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.021_bib31","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-term follow-up","volume":"29","author":"Bj\u00f6rkstrand","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.021_bib32","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2015.07.021_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1586\/17474086.2014.857270","article-title":"Allogeneic transplantation in multiple myeloma","volume":"7","author":"Gahrton","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bbmt.2015.07.021_bib34","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/CCO.0b013e328358f619","article-title":"Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care","volume":"24","author":"Koehne","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.021_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"De Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.021_bib36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib37","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.07.021_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.07.021_bib39","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 2009. v4.03: June 14, 2010. Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed July 3,\u00a02015."},{"key":"10.1016\/j.bbmt.2015.07.021_bib40","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib41","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbmt.2014.12.026","article-title":"Management of relapsed multiple myeloma after autologous stem cell transplant","volume":"21","author":"Holstein","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib43","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A\u00a0phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.021_bib44","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bbmt.2008.05.010","article-title":"Transplantation from matched siblings using once-daily intravenous busulfan\/fludarabine with Thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease","volume":"14","author":"Russell","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib45","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.bbmt.2013.07.008","article-title":"A\u00a0randomized phase II trial of fludarabine\/melphalan 100 versus fludarabine\/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma","volume":"19","author":"Bashir","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib46","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/bmt.2013.37","article-title":"Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma","volume":"48","author":"Nishihori","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.021_bib47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.07.021_bib48","unstructured":"BMTCTN website. Available at: https:\/\/web.emmes.com\/study\/bmt2\/protocol\/1302_protocol\/1302_protocol.html. Accessed June 30,\u00a02015."}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911500498X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911500498X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:53:20Z","timestamp":1761058400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911500498X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S108387911500498X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.021","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}